Renaissance to in-license St Jude’s humanised monoclonal antibody
临床结果引进/卖出免疫疗法临床2期
Preview
来源: Pharmaceutical Technology
Hu14.18 is in development for the treatment of newly diagnosed high-risk neuroblastoma. Credit: Kateryna Kon/Shutterstock.com.
Renaissance Pharma has signed an agreement to in-license St Jude Children’s Research Hospital’s Hu14.18K322A (Hu14.18), an anti-GD2 humanised monoclonal antibody (mAb) in development for treating newly diagnosed high-risk neuroblastoma (HRNB).
According to the agreement, Renaissance gained exclusive development, manufacturing and commercialisation rights to Turkey, Japan, Europe, China, Canada, and the US.
Recommended Reports
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - CD19 Antibody GlobalData
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Monoclonal Antibody Conjugate to Target GPC1 for Oncology GlobalData
View allCompanies IntelligenceSt. Jude Children’s Research Hospital IncEuropean Medicines AgencyRenaissance IncSt JudeRenaissance Pharma, Inc.View all
The company will now interact with the Food and Drug Administration (FDA), European Medicines Agency (EMA) and other regulatory agencies for seeking approval in their respective countries.
Hu14.18 has demonstrated favourable patient outcomes with overall survival of 86% and event-free survival of 73.7% in a Phase II trial.
In the trial, Hu14.18 was used as induction therapy and additionally, within post-consolidation therapy.
Out of the total patients treated, 66.7% achieved a partial response or better after the first two chemo-immunotherapy induction cycles while 96.8% achieved the same at the end of induction.
Renaissance Pharma CEO Simon Ball said: “Renaissance Pharma now has its full attention on bringing this humanised antibody to market as expeditiously as possible.
“The collaboration with St Jude marks the intention of Renaissance and we must now play our part in making the product available.”
An estimated 300 patients are diagnosed with HRNB in the US and 500 in Europe. This high-risk disease is said to be the most common cancer in children under one year of age.
They are currently treated with surgery, radiotherapy, stem cell transplantation, and multiple cycles of chemotherapy.
St Jude’s paediatric oncologist Sara Federico said: “It is exciting and deeply meaningful to see how our clinical efforts to develop Hu14.18 may now have the potential to positively impact patients with high-risk neuroblastoma around the world.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
药物
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。